 |
|
Artificial pump effectively backs up failing hearts
April 03, 2009Patients with severe heart failure can be bridged to eventual transplant by a new, smaller and lighter implantable heart pump, according to a just-completed study of the device. Results of this third-generation heart assist device were reported at the 58th annual meeting of the American College of Cardiology on March 30.
The device, called a left ventricular assist device (LVAD), is the latest generation of heart assist devices. The LVAD was tested at five main sites: Washington University School of Medicine in St. Louis, the University of Minnesota, Mt. Sinai School of Medicine, Inova Fairfax Hospital and the University of Pittsburgh.
"LVADs have allowed us to support patients until they can receive a heart transplant, so they are called a bridge to transplant," says Gregory Ewald, M.D., a Washington University cardiologist at Barnes-Jewish Hospital and medical director of the Heart Failure, Cardiac Transplantation and Total Artificial Heart Program. "For patients whose hearts are failing and are awaiting transplantation, these devices can be lifesavers. Washington University is the only medical center in the region where patients can receive these devices at this time."
In addition to Ewald, associate professor of medicine, lead investigators in the trial included Nader Moazami, M.D., associate professor of surgery and surgical director of the Cardiac Transplantation and Total Artificial Heart Program at Washington University, and Andrew Boyle, M.D., associate professor of medicine at the University of Minnesota and medical director of Heart Failure, Cardiac Transplantation and Mechanical Circulatory Support. Boyle presented the findings at the ACC meeting.
An LVAD is implanted inside the chest cavity near the heart and is connected to the heart's left ventricle (pumping chamber). It assists the patient's weakened or damaged ventricle in pumping blood through the body. By restoring a normal blood flow, the device improves patients' health. Because it is powered by portable battery packs, patients usually go home while they wait for a heart transplant.
The LVAD used in this study, the VentrAssist, is termed a third-generation heart assist device. Measuring 2.5-inches across and weighing 10 ounces, the pump is considered an improvement over earlier devices because its size and light weight make it suitable for small adults and children. In addition, its pumping mechanism has no contacting parts for improved durability.
Patients who received the LVAD in the study were approved and listed for cardiac transplantation. The study considered the device successful if a patient survived until heart transplantation or survived at least 180 days after the device was implanted and remained qualified for heart transplantation. Eighty-five percent of patients met this measure of success.
Out of 98 patients who received the device, 60 were transplanted, 19 continued to be supported with the device and 19 died. The median time on LVAD support was 131 days. Adverse events reported during the trial included stroke and bleeding, and the number and type of adverse events was similar to other LVADs but better than that of first-generation VAD devices.
Answering standardized questionnaires for patients with heart failure, they reported a significantly improved quality of life after receiving the device, indicating that their heart failure was less apt to interfere with everyday activities such as housework, hobbies or sleeping or to affect their mood, ability to concentrate or energy level.
"Before implantation of the device, 80 percent of these patients were rated class four on the New York Heart Association scale - they were short of breath at rest," Ewald says. "But by six months, 84 percent were in class one or two, meaning their heart failure symptoms were minimal or mild. All of them were able to go home with the device, and that allowed them to rehabilitate themselves - their nutrition improved and they were in better shape, making them better candidates for heart transplantation."
The VentrAssist device pumps blood in a continuous flow in contrast to earlier heart assist pumps that pumped blood in pulses. It contains a spinning rotor that is suspended by blood within the pump housing and magnetically rotated. Since the impeller blades don't touch any part of the pump, the chance of damage to blood cells is lessened. With only one moving part, the pump is resistant to wear.
The positive results from this clinical study mean the VentrAssist will be submitted to the U.S. Food and Drug Administration for approval for use as a bridge to heart transplant. In the interim, Washington University School of Medicine will continue to provide the device to patients as part of a clinical trial.
Doctors here are continuing to enroll patients in a trial of the device as a bridge to transplantation, and they are also testing the device as "destination therapy" to see if the device can function as an alternative to heart transplant by permanently assisting failing hearts. For information about enrolling in the trials call 314-454-7687.
Washington University School of Medicine in St. Louis
In addition to Ewald, associate professor of medicine, lead investigators in the trial included Nader Moazami, M.D., associate professor of surgery and surgical director of the Cardiac Transplantation and Total Artificial Heart Program at Washington University, and Andrew Boyle, M.D., associate professor of medicine at the University of Minnesota and medical director of Heart Failure, Cardiac Transplantation and Mechanical Circulatory Support. Boyle presented the findings at the ACC meeting.
An LVAD is implanted inside the chest cavity near the heart and is connected to the heart's left ventricle (pumping chamber). It assists the patient's weakened or damaged ventricle in pumping blood through the body. By restoring a normal blood flow, the device improves patients' health. Because it is powered by portable battery packs, patients usually go home while they wait for a heart transplant.
The LVAD used in this study, the VentrAssist, is termed a third-generation heart assist device. Measuring 2.5-inches across and weighing 10 ounces, the pump is considered an improvement over earlier devices because its size and light weight make it suitable for small adults and children. In addition, its pumping mechanism has no contacting parts for improved durability.
Patients who received the LVAD in the study were approved and listed for cardiac transplantation. The study considered the device successful if a patient survived until heart transplantation or survived at least 180 days after the device was implanted and remained qualified for heart transplantation. Eighty-five percent of patients met this measure of success.
Out of 98 patients who received the device, 60 were transplanted, 19 continued to be supported with the device and 19 died. The median time on LVAD support was 131 days. Adverse events reported during the trial included stroke and bleeding, and the number and type of adverse events was similar to other LVADs but better than that of first-generation VAD devices.
Answering standardized questionnaires for patients with heart failure, they reported a significantly improved quality of life after receiving the device, indicating that their heart failure was less apt to interfere with everyday activities such as housework, hobbies or sleeping or to affect their mood, ability to concentrate or energy level.
"Before implantation of the device, 80 percent of these patients were rated class four on the New York Heart Association scale - they were short of breath at rest," Ewald says. "But by six months, 84 percent were in class one or two, meaning their heart failure symptoms were minimal or mild. All of them were able to go home with the device, and that allowed them to rehabilitate themselves - their nutrition improved and they were in better shape, making them better candidates for heart transplantation."
The VentrAssist device pumps blood in a continuous flow in contrast to earlier heart assist pumps that pumped blood in pulses. It contains a spinning rotor that is suspended by blood within the pump housing and magnetically rotated. Since the impeller blades don't touch any part of the pump, the chance of damage to blood cells is lessened. With only one moving part, the pump is resistant to wear.
The positive results from this clinical study mean the VentrAssist will be submitted to the U.S. Food and Drug Administration for approval for use as a bridge to heart transplant. In the interim, Washington University School of Medicine will continue to provide the device to patients as part of a clinical trial.
Doctors here are continuing to enroll patients in a trial of the device as a bridge to transplantation, and they are also testing the device as "destination therapy" to see if the device can function as an alternative to heart transplant by permanently assisting failing hearts. For information about enrolling in the trials call 314-454-7687.
Washington University School of Medicine in St. Louis
Heart Transplant Current Events and Heart Transplant News RSSYoung athletes need dual screening tests for heart defects, study suggests
To best detect early signs of life-threatening heart defects in young athletes, screening programs should include both popular diagnostic tests, not just one of them, according to new research from heart experts at Johns Hopkins.
Texas Children's discharges first pediatric patient with implanted mechanical heart device
Texas Children's Hospital is the nation's first pediatric hospital to discharge a child while on an intracorporeal ventricular assist device (VAD), a feat previously accomplished only at adult institutions.
UT Southwestern patient first in North Texas to receive newest-generation heart failure device
UT Southwestern Medical Center patient Michael LeBlanc, 40, is the first in North Texas to receive the newest generation of a mechanical device designed to improve heart function. It will be his lifeline while he awaits a heart transplant.
Heart transplant recipients can improve fitness and perform high intensity workouts
Heart transplant recipients' cardio-respiratory fitness is around 30 to 50 per cent lower than age-matched healthy sedentary individuals.
First heart patients implanted with next-generation mechanical heart pump
Three patients at NewYork-Presbyterian Hospital/Columbia University Medical Center were among the first in the United States to be implanted with a next-generation artificial heart pump called the DuraHeart™ Left-Ventricular Assist System.
Exercise is safe, improves quality of life in patients with chronic heart failure
Regular exercise is safe for heart failure patients and may slightly lower their risk of death or hospitalization, according to results from the largest and most comprehensive clinical trial to examine the effects of exercise in chronic heart failure patients.
Older patients with 1 type of heart failure may receive little or no benefit from drugs
People over 80 years of age suffering from a certain type of heart failure do not appear to benefit from most commonly prescribed heart medications, according to a study conducted at the Cedars-Sinai Heart Institute and published in the March 15 issue of The American Journal of Cardiology.
Hebrew University scientist develop technique for eliminating reblockage of arteries
An easily implementable technique to avoid reblockage of arteries that have been cleared through angioplasty and stent insertion has been developed by researchers led by Prof. Boris Rubinsky of the Hebrew University of Jerusalem.
First Trial in the U.S. to Treat Both Ischemic & Non-Ischemic Heart Failure to be Performed by U of U Researchers Using Patient's Own Stem Cells
Researchers at the University of Utah are enrolling people in a new clinical trial that uses a patient's own stem cells to treat ischemic and non-ischemic heart failure.
First gene therapy for heart failure offered at NewYork-Presbyterian/Columbia
Could injecting a gene into a patient with severe heart failure reverse their disabling and life-threatening condition? Physician-scientists are setting out to answer that question in a first-ever clinical trial of gene therapy to treat severe heart failure.
More Heart Transplant Current Events and Heart Transplant News Articles
 |
Dying to Live: From Heart Transplant to Abundant Life by Gaea Shaw (Author) Dying to Live is about facing challenges. Being miserable. Finding faith. Letting go and learning to trust. It is the inspiring story of Gaea Shaw’s journey from heart transplant recipient to gold medal winner at the Olympic-style Transplant Games. But Gaea’s story is much more than that. Her gift to readers is that she encourages each of us to see that we all face our own challenges—and that each of us can experience an abundant life, filled with gratitude, no matter what the odds. |
 |
The Grateful Heart: Diary of a Heart Transplant by Candace C. Moose (Author) In August 2001 the author received immunizations in anticipation of travel to Africa to help children suffering from HIV/AIDS. Soon after the shots, she feel prey to an extraordinarily rare and generally fatal disease. She received a heart transplant 7 weeks later, and fought bravely and successfully to overcome many obstacles in her recovery. She received caring help from many hands as she healed. This book is an expression of her faith and her gratefulness. |
 |
Heart Condition Starring: Bob Hoskins, Denzel Washington, Chloe Webb, Roger E. Mosley, Ja'net DuBois Directed By: James D. Parriott A racist LAPD officer loses his girlfriend to a black lawyer. When the lawyer is murdered, his heart is transplanted into the officer, who has just suffered a heart attack. When the officer awakens from the transplant, he finds the lawyer's ghost is his constant companion. |
 |
Stories of the Heart: Reflections on the Heart Transplant Journey : Stories of Hope and Inspiration by Nancy Siemers (Editor) A collection of powerful stories told by 50 persons who have been through the heart transplant experience. The reader is drawn int the sorrows, joys, ironies, and trials of people living live at the edge. Death, suffering, rebirth, and humor are the stuff of great literature. This is great literature. |
 |
Soul Heart Transplant: The Lamp Sessions by Ebony Rhythm Band |
 |
Heart Transplant Melody Meets Me (Primary Contributor) |
 |
2008 Upper Deck (UD) A Piece of History # 185 1st Heart Transplant ( Historical Moment ) MLB Baseball Trading Card in a Protective Screw Down Display Case by Upper Deck 2008 Upper Deck (UD) A Piece of History # 185 1st Heart Transplant ( Historical Moment ) MLB Baseball Trading Card in a Protective Screw Down Display Case |
|
Mavericks, Miracles & Medicine (Set of 2 VHS Tapes) Vol. 1 The Heart/transplants Vol. 2 The Brain/infectious Disease A & E Videos capture the glory, tragedy, and drama of human experience. Brilliant specials, astounding documentaries, and vibrant dramatizations bring the past home to you. | |
 |
Safe Starring: Michelle Trachtenberg, Mel Harris, Jake McDorman, Lance Guest Directed By: Felix Alcala Also With: Bryan Singer (Producer), David Shore (Producer), Paul Attanasio (Producer), Katie Jacobs (Producer), Russel Friend (Producer), Garrett Lerner (Producer), Doris Egan (Producer), Thomas L. Moran (Producer), David Semel (Producer), Peter Blake (Writer) |
 |
Miraculous Heart Transplant Saint Catherine of Siena Exchanges Hearts, Temporarily, with Jesus Religion & Philosophy Giclee Poster Print, 24x32 by Art.com Art.com is the world's largest retailer of art prints, posters, photographs, and framed artwork. With our huge selection of over 400,000 prints, you'll easily find the perfect piece for your home, office, or classroom. Our art is printed on quality paper. When you order framed artwork, the piece is built by our team of in-house professionals. Visit our Amazon store today at www.amazon.com/artdotcom to find Special Offers and search for products based on 'Artist Name' and 'Subject Categories' such as Movie, Music, Vintage, TV, Children, Travel, Kitchen, Museum Art, Animals, Floral, Motivational, and Sports. Art.com is dedicated to providing you with high quality products and service by offering you 100% satisfaction guaranteed. We ship internationally to over 80 countries. Decorate your... |
| © 2009 BrightSurf.com |